DER BETA-BLOCKER PINDOLOL IN DER THERAPIE DER ANGINA PECTORIS: BERICH UEBER EINE MULTIZENTRISCHE KONTROLLIERTE STUDIE = LE PINDOLOL, BETA -BLOQUANT, DANS LA THERAPEUTIQUE DE L'ANGINE DE POITRINE: ETUDE MULTICENTRIQUE CONTROLEELANG E; FITSCHA P; SCHIESS W et al.1979; WIEN. MED. WSCHR.; AUT; DA. 1979; VOL. 129; NO 17; PP. 484-488; ABS. ENG; BIBL. 25 REF.Article

HYPERTENSION AND BENEFICIAL TREATMENT WITH BETA -BLOCKING AGENTS DOES NOT CHANGE THE PLATELET SENSITIVITY TO THE ANTIAGGREGATORY PROSTAGLANDINSSINZINGER H; FITSCHA P; KALIMAN J et al.1982; PROSTAGLANDINS LEUKOT. MED.; ISSN 0262-1746; GBR; DA. 1982; VOL. 9; NO 3; PP. 301-305; BIBL. 14 REF.Article

DIE BEDEUTUNG DER LANGZEIT-EKG-UEBERWACHUNG ZUR ERFASSUNG VON ARRHYTHMIEN = L'IMPORTANCE DE LA SURVEILLANCE ECG A LONG TERME POUR LE DEPISTAGE DES ARYTHMIESFITSCHA P; TISO B; MEISNER W et al.1981; WIEN. KLIN. WOCHENSCHR.; ISSN 0043-5325; AUT; DA. 1981; VOL. 93; NO 2; PP. 39-45; ABS. ENG; BIBL. 54 REF.Article

Platelet-modifying drugs for cerebrovascular disordersFITSCHA, P; O'GRADY, J.Thrombotic and haemorrhagic disorders. 1991, Vol 3, Num 2, pp 33-36, 4 p.Article

Die Bedeutung von Thrombozyten und Plasma für die Hämostase-Regulation bei Typ-II-Diabetikern = L'importance des thrombocytes et du plasma pour la régulation de l'hémostase chez les diabétiques de type II = The influence of platelets and plasma on the hemostatic regulation in diabeticsSINZINGER, H; FITSCHA, P.VASA. 1985, Vol 14, Num 2, pp 121-124, issn 0301-1526Article

Prostacyclin (PGI₂) contracts normal and varicose human saphenous veinsSINZINGER, H; FITSCHA, P.VASA. 1984, Vol 13, Num 3, pp 228-230, issn 0301-1526Article

RUHE- UND BELASTUNGSHAEMODYNAMIK VOR UND NACH REHABILITATION BEIM AKUTEN MYOKARDINFARKT = HEMODYNAMIQUE DE REPOS ET D'EFFORT AVANT ET APRES REEDUCATION DANS L'INFARCTUS DU MYOCARDEFITSCHA P; TISO B; MEISNER W et al.1981; WIEN. KLIN. WOCHENSCHR.; ISSN 0043-5325; AUT; DA. 1981; VOL. 93; NO 2; PP. 45-49; BIBL. 34 REF.Article

PINDOLOL ALS ANTIHYPERTENSIVUM. = LE PINDOLOL EN TANT QU'ANTIHYPERTENSEURPINGGERA WF; FITSCHA P; STUMMVOLL HK et al.1977; FORTSCHR. D. MED.; DTSCH.; DA. 1977; VOL. 95; NO 5; PP. 310-314 (5P.); ABS. ANGL.; BIBL. 18 REF.Article

Jogging causes a significant increase in platelet sensitivity to prostacyclinSINZINGER, H; FITSCHA, P.International journal of sports medicine. 1986, Vol 7, Num 6, pp 338-341, issn 0172-4622Article

ECHOKARDIOGRAPHISCHE DIAGNOSE EINES FALLES VON SUBPULMONALSTENOSE BEI HYPERTROPHER KARDIOMYOPATHIE (BERNHEIM-SYNDROM) = DIAGNOSTIC ECHOCARDIOGRAPHIQUE DE L'OBSTRUCTION PULMONAIRE SOUSVALVULAIRE DANS LA CARDIOMYOPATHIE HYPERTROPHIQUEKRONIK G; FITSCHA P; SLANY J et al.1979; Z. KARDIOL.; DEU; DA. 1979; VOL. 68; NO 6; PP. 415-418; ABS. ENG; BIBL. 15 REF.Article

Evaluation of isradipine and captopril alone or in combination for the treatment of hypertensionFITSCHA, P; MEISNER, W; HITZENBERGER, G et al.Journal of cardiovascular pharmacology. 1991, Vol 18, pp S12-S14, issn 0160-2446, SUP3Article

Comparison of bopindolol and atenolol in chronic stable angina pectorisFITSCHA, P; MEISNER, W; TISO, B et al.European journal of clinical pharmacology. 1990, Vol 38, Num 1, pp 81-84, issn 0031-6970Article

Effects of taprostene, a stable prostacyclin analogue, on haemodynamics, platelet function and arachidonate metabolism in healthy volunteersVIRGOLINI, I; FITSCHA, P; SINZINGER, H et al.European journal of clinical pharmacology. 1990, Vol 38, Num 4, pp 347-350, issn 0031-6970Article

Ispradipine: a potent calcium blocker with beneficial effects on platelet function and vascular prostacyclin productionWEISS, K; FITSCHA, P; O'GRADY, J et al.Thrombosis research. 1989, Vol 54, Num 4, pp 311-317, issn 0049-3848Article

Pathomechanisms of atherosclerosis beneficially affected by prostaglandin E₁ (PGE₁): an updateSINZINGER, H; VIRGOLINI, I; FITSCHA, P et al.Vasa. Supplementum. 1989, Vol 28, pp 6-13, issn 0251-1029Article

Platelet kinetics in patients with atherosclerosisSINZINGER, H; VIRGOLINI, I; FITSCHA, P et al.Thrombosis research. 1990, Vol 57, Num 4, pp 507-516, issn 0049-3848, 10 p.Article

Platelet deposition on human atherosclerotic lesions is decreased by low-dose aspirin in combination with dipyridamoleSINZINGER, H; ÓGRADY, J; FITSCHA, P et al.Journal of international medical research. 1988, Vol 16, Num 1, pp 39-43, issn 0300-0605Article

Diminished platelet residence time on active human atherosclerotic lesions in-vivo, evidence for an optimal dose of aspirin?SINZINGER, H; KALIMAN, J; FITSCHA, P et al.Prostaglandins, leukotrienes and essential fatty acids. 1988, Vol 34, Num 2, pp 89-93, issn 0952-3278Article

Prostaglandin I₂ and the nitric oxide donor molsidomine have synergistic effects on thromboresistance in manSINZINGER, H; RAUSCHA, F; O'GRADY, J et al.British journal of clinical pharmacology. 1992, Vol 33, Num 3, pp 289-292, issn 0306-5251Article

Prevalence of a shortened prostacyclin half-life in plasma in healthy adults : results of a screening investigationSINZINGER, H; RAUSCHA, F; FITSCHA, P et al.American journal of hematology. 1990, Vol 33, Num 2, pp 139-141, issn 0361-8609Article

Glucocorticoid-treatment does not influence the synthesis of thromboxane B₂ and bicyclo-PGE₂ in humansSINZINGER, H; VIRGOLINI, I; RAUSCHA, F et al.Prostaglandins, leukotrienes and essential fatty acids. 1989, Vol 35, Num 3, pp 135-139, issn 0952-3278, 5 p.Article

Prostaglandin 12 during radiolabelling improves recovery, but does not change platelet half-life and platelet uptake over active human lesion sitesSINZINGER, H; FITSCHA, P; KALIMAN, J et al.Prostaglandins. 1987, Vol 33, Num 6, pp 783-788, issn 0090-6980Article

Prostaglandin E₁-therapy reduces circulating adhesion molecules (ICAM-1, E-selectin, VCAM-1) in peripheral vascular diseasePALUMBO, B; OGUOGHO, A; FITSCHA, P et al.VASA. 2000, Vol 29, Num 3, pp 179-185, issn 0301-1526Article

Haemodynamic effects of short-term treatment with bopindolol in essential hypertensionFITSCHA, P; MEISNER, W; BRANDSTETTER, G et al.European journal of clinical pharmacology. 1988, Vol 34, Num 4, pp 411-413, issn 0031-6970Article

20 mg Aspirin daily ― evidence for a clinical future of this extremely low-dose in arterial disease?SINZINGER, H; SILBERBAUER, K; KALIMAN, J et al.VASA. 1988, Vol 17, Num 1, pp 10-15, issn 0301-1526Article